Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy

Return to Grants

Grant Award Details

Grant Type:

Progression Award – Discovery Stage Research Projects

Grant Number:

DISC2P-11946

Investigator(s):

Name:

5106433559 Kevin E. Healy

Institution:

University of California, Berkeley

Type:

PI

Disease Focus:

COVID-19, Infectious Disease

Human Stem Cell Use:

Award Value:

$224,500

Status:

Closed

Progress Reports

Reporting Period:

Year 1

Grant Application Details

Application Title:

Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy

Publications

Front Pharmacol (2021): Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics. (PubMed: 34421592)
Clin Transl Sci (2021): In vitro safety “clinical trial” of the cardiac liability of drug polytherapy. (PubMed: 33786981)
bioRxiv (2020): In Vitro Safety “Clinical Trial” of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy. (PubMed: 33398282)